Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
14 hedge funds and large institutions have $9.2M invested in Yield10 Bioscience, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more capital invested
Capital invested by funds: $6.13M → $9.2M (+$3.07M)
8% more funds holding
Funds holding: 13 → 14 (+1)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.68M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$86.4K |
| 3 |
Goldman Sachs
New York
|
+$43.2K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$43.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$432K |
| 2 |
FA
FCG Advisors
Chatham,
New Jersey
|
-$86.4K |
| 3 |
Renaissance Technologies
New York
|
-$49K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$43.2K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$18K |
YTEN Hedge Fund Activity: Q3 2014 in Review
14 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q3 2014, worth a combined $9.2M — up 50% from $6.13M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new YTEN positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Oracle Investment Management, adding an estimated $2.68M. The largest seller was Fidelity Investments, cutting an estimated $432K.
- 14 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q3 2014, up from 13 in Q2 2014.
- Funds reported $9.2M of Yield10 Bioscience, Inc. Common Stock stock for Q3 2014, up 50% quarter-over-quarter.
- 2 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q3 2014 and 1 closed out, a net change of +1 holder.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q3 2014 was Oracle Investment Management, an estimated $2.68M added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q3 2014 was Fidelity Investments, an estimated $432K sold.
Based on aggregated 13F filings for Q3 2014.